Pharmacokinetics of L-FMAUS, a new antiviral agent, after intravenous and oral administration to rats: Contribution of gastrointestinal first-pass effect to low bioavailability

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 4, 2007, Pages 187-197

  Chung, Hye J ^a   Lee, Joo H ^a   Woo, Sung J ^b   Park, Hee K ^b   Koo, Chang H ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Bukwang Pharmaceutical Company   (South Korea)

Author keywords

Gastrointestinal first pass effect; L FMAUS; Pharmacokinetics; Rats

Indexed keywords

ANTIVIRUS AGENT; CLEVUDINE; NEW DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; FIRST PASS EFFECT; GASTROINTESTINAL TRACT; HEART; IN VITRO STUDY; LIVER; LUNG; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; RAT; STOMACH JUICE;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG STABILITY; HALF-LIFE; INFUSIONS, INTRAVENOUS; INTESTINES; MALE; PYRIMIDINE NUCLEOSIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34249699482     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.545     Document Type: Article

References (27)

1. Chu CK, Ma T, Shanmuganathan K, et al. Use of 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39: 979-981.
2. Koo CH, Park KS, Moon JT, Woo SJ, Lee DH. Sulfur derivatives of 2′-fluoro-5-methyl-β-L-arabinofuranosyluridine. Korea Patent 2005; 10-0487992.
3. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1993; 65: 55-63.
4. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
5. Chung HJ, Kim YC, Koo CH, Lee MG. Determination of 1-(3-fluoro-4-hydroxy-5-mercaptomethyltetrahydrofuran- 2-yl)-5-methyl-1H-pyrimidine-2,4-dione in rat plasma and urine by high-performance liquid chromatography. J Chromatogr B 2004; 803: 367-370.
6. Xu Z-X, Tang J-P, Badr M, Melethil S. Kinetics of aluminum in rats. III: effect of route of administration. J Pharm Sci 1992; 81: 160-163.
7. Kim J, Kim SH, Lee MG. Liver and gastrointestinal first-pass effects of azosemide in rats. J Pharm Pharmacol 1997; 49:878-883.
8. Yu SY, Bae SK, Kim EJ, et al. Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect. J Pharm Sci 2003; 92: 1592-1603.
9. Lee MG, Chen M-L, Huang S-M, Chiou WL. Pharmacokinetics of drugs in blood I. Unusual distribution of gentamicin. Biopharm Drug Dispos 1981; 2: 89-97.
10. Shim HJ, Lee EJ, Kim SH, et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 2000; 21: 285-291.
11. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-549.
12. Gibaldi M, Perrier D. Pharmacokinetics (2nd edn). Marcel Dekker Inc.: New York, 1982.
13. Chiou WL. New calculation method of mean total body clearance of drugs and its application to dosage regimens. J Pharm Sci 1980; 69: 90-91.
14. Eatman FB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.
15. Chiou WL. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 1979; 68: 1067-1069.
16. Chiou WL. Potential pitfalls in the conventional pharmacokinetic studies: effects of the initial mixing of drug in blood and the pulmonary first-pass elimination. J Pharmacokinet Biopharm 1979; 7: 527-536.
17. Lee H-J, Chiou WL. Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin. Pharm Res 1989; 6: 833-839.
18. Lee H-J, Chiou WL. Erythrocytes as barriers for drug elimination in the isolated rat liver. II. Propranolol. Pharm Res 1989; 6: 840-843.
19. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
20. Mitruka BM, Rawnsley HM. Clinical Biomedical and Hematological Reference Values in Normal Experimental Animals and Normal Humans (2nd edn). Masson Publishing USA Inc.: New York, 1981.
21. Bae SK, Chung W-S, Kim EJ, et al. Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob Agents Chemother 2004; 48: 659-662.
22. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-640.
23. Bramer SL, Au JL, Wientjes MG. Gastrointestinal and hepatic first-pass elimination of 2′,3′-dideoxyinosine in rats. J Pharmacol Exp Ther 1993; 265: 731-738.
24. Morse GD, Shelton MJ, O'Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 1993; 24: 101-123.
25. Arnér ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995; 67: 155-186.
26. Spasokoukotskaja T, Arnér ES, Brosjo O, et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer 1995; 31A: 202-208.
27. Liu SH, Grove KL, Cheng YC. Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fluoro-5-methyl-β-L-arbinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother 1998; 42: 833-839.